miR‐210 in Ischemic Cardiovascular Disease: Functions, Mechanisms, and Therapeutic Potential
Advanced Biology · 2026-05 · 10 (5)
DOI: 10.1002/adbi.202500653 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Biology, online erschienen am 18.05.2026. Verfasst von Wanqiu Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shandong Provincial Key Medical and Health Laboratory of Endocrinology and Metabolic Diseases, Affiliated…. Hauptthemen laut MEDLINE: MicroRNAs, Myocardial Ischemia, Cardiovascular Diseases. Die Arbeit nennt 81 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Natural Science Foundation of Shandong Province, Young Talent of Lifting engineering for Science and Technology in Shandong.
Abstract (Originalsprache)
Ischemic cardiovascular disease remains a leading cause of morbidity and mortality worldwide despite advances in pharmacological, interventional, and rehabilitative therapies. Hypoxia‐inducible microRNA‐210 (miR‐210) has emerged as a central mediator of cellular adaptation to oxygen deprivation and ischemic injury. As a prototypical “hypoxamir,” miR‐210 regulates metabolic reprogramming, apoptosis, angiogenesis, and vascular remodeling, thereby influencing disease onset, progression, and repair. Its expression is governed by transcription factors, while downstream targets modulate mitochondrial function, DNA repair, and apoptotic signaling. Functionally, miR‐210 enhances cardiomyocyte survival, promotes endothelial migration and tube formation, attenuates fibrosis, and supports stem cell adaptation. Clinical studies reveal that circulating and exosomal miR‐210 correlate with infarct size, collateral formation, and prognosis, suggesting biomarker potential. Preclinical evidence further highlights therapeutic applications through mimics, antagomirs, nanoparticles, and stem cell–derived exosomes, though delivery and safety challenges remain. This review aims to synthesize current knowledge on the regulatory network and functional roles of miR‐210 in ischemic cardiovascular disease, and to evaluate its prospects as both a biomarker and a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shandong Provincial Key Medical and Health Laboratory of Endocrinology and Metabolic Diseases, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
- Clinical Research Center, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
- Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Xiaodong Sun
Förderung
- National Natural Science Foundation of China
- National Natural Science Foundation of Shandong Province
- Young Talent of Lifting engineering for Science and Technology in Shandong
- Youth Innovation and Technology Support Program of Shandong Higher Education Institution
Zitieren
APA
Zhang, W., Zhang, K., Ma, Y., Tian, Z., Kan, C., Zhang, J., & Sun, X. (2026). miR‐210 in Ischemic Cardiovascular Disease: Functions, Mechanisms, and Therapeutic Potential. Advanced Biology, 10(5). https://doi.org/10.1002/adbi.202500653
Vancouver
Zhang W, Zhang K, Ma Y, Tian Z, Kan C, Zhang J, et al. miR‐210 in Ischemic Cardiovascular Disease: Functions, Mechanisms, and Therapeutic Potential. Advanced Biology. 2026;10(5). doi:10.1002/adbi.202500653
BibTeX
@article{Zhang2026,
author = {Zhang, Wanqiu and Zhang, Kexin and Ma, Yujie and Tian, Zhenghui and Kan, Chengxia and Zhang, Jingwen and Sun, Xiaodong},
title = {miR‐210 in Ischemic Cardiovascular Disease: Functions, Mechanisms, and Therapeutic Potential},
journal = {Advanced Biology},
year = {2026},
volume = {10},
number = {5},
doi = {10.1002/adbi.202500653}
}
EUVIMED